Illumina to divest cancer test maker Grail after antitrust battles
San Diego-based biotech company Illumina announced on Monday its decision to divest cancer test maker Grail after facing prolonged antitrust battles. The move comes as a strategic step aimed at addressing regulatory concerns and facilitating the acquisition process of Grail by a group of investment firms.
